TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

Clinical Breast Cancer

Volumn 9, Issue 4, 2009, Pages 258-261

  MacKey, John ^a   Gelmon, Karen ^b   Martin, Miguel ^c   McCarthy, Nicole ^d   Pinter, Tamas ^e   Rupin, Mathieu ^f   Youssoufian, Hagop ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e Petz Alador Country Hospital   (Hungary)

^f Cancer International Research Group   (France)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis inhibitor; Bevacizumab; Ramucirumab; Vascular endothelial growth factor receptor

Indexed keywords

ANGIOGENESIS INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMC 1121B; PLACEBO; RAMUCIRUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 73349135923     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.044     Document Type: Article

References (18)

1. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10:1706-1716
2. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
3. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Amer Soc Clin Oncol 2008; 26:15s (Abstract LBA 1011).
4. Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008; 6:1630-1638
5. Ghosh S, Sullivan CA, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008; 39:1835-1843.
6. Price DJ, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12:129-135
7. Skobe M, Rockwell P, Goldstein N, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3:1222-1227
8. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59:5209-5218
9. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-3372
10. Hotchkiss KA, Ashton AW, Sparano J, et al. Inhibition of endothelial cell function by docetaxel (Taxotere). Proc Am Assoc Cancer Res 2000; 41:647.
11. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24:4963-4970
12. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313
13. Martín M, Lluch A, Seguí MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17:1181-1183
14. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381-5387
15. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial [Erratum in: J Clin Oncol 2007; 25:5048]. J Clin Oncol 2007; 25:2678-2684
16. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer [Erratum in: J Clin Oncol 2006; 24:3515]. J Clin Oncol 2006; 24:1831-1838.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
18. EaST 5. Cambridge, MA: Cytel Statistical Software & Services; 2007.